Taking the negative view of current migraine treatments: The unmet needs

CNS Drugs

Volumn 26, Issue 5, 2012, Pages 375-382

  Tfelt Hansen, Peer ^a   Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Frovatriptan; Migraine; Propranolol; Rizatriptan; Topiramate; Tryptamines; Valproate

Indexed keywords

ALMOTRIPTAN; BOTULINUM TOXIN A; ELETRIPTAN; FLUNARIZINE; FROVATRIPTAN; METOPROLOL; NAPROXEN; NARATRIPTAN; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROIC ACID; ZOLMITRIPTAN;

ANALGESIA; BEHAVIOR THERAPY; BODY WEIGHT; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEPATITIS; HUMAN; LANGUAGE DISABILITY; MEMORY DISORDER; META ANALYSIS (TOPIC); MIGRAINE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADULT; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MIGRAINE DISORDERS; TRYPTAMINES;

EID: 84859973074     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11630590-000000000-00000     Document Type: Review

References (47)

1. Dahlöf C, Hogenhuis L, Olesen J, et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998;5: 469-77 (Pubitemid 28470001)
2. Tfelt-Hansen P. Parenteral versus oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 2007;8: 273-6 (Pubitemid 350214724)
3. Tfelt-Hansen P. Maximum effect of triptans? A comment. Cephalalgia 2008;28: 767-8
4. Treatment of migraine attacks with sumatriptan: the Subcutaneous Sumatriptan International Study Group. N Eng J Med 1991;325: 316-21
5. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265: 2831-5
6. Tfelt-Hansen P. Excellent tolerability but relative low initial efficacy of telcagepant in the treatment of migraine. Headache 2011;51: 118-23
7. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22: 633-56
8. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams &Wilkins, 2006: 469-503
9. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy of tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005;30: 521-32 (Pubitemid 43960978)
10. Kramer MS, Matzura-Wolf D, Polis A, et al. A placebocontrolled crossover study of rizatriptan in the treatment of multiple migraine attacks: Rizatriptan Multiple Attack Study Group. Neurology 1998;51: 773-81 (Pubitemid 28449258)
11. Diener H-C, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011;31: 573-84
12. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20: 765-86 (Pubitemid 32154559)
13. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39 Suppl. 2: S20-6 (Pubitemid 30002025)
14. Lantéri-Minet M, Massiou H, Romatet S, et al. An instrument to assess patient perception of satisfaction with acute migraine treatment (EXPERT Study). Headache 2011;51: 590-601
15. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007;21: 877-83 (Pubitemid 47557103)
16. Bigal ME, Borucho S, Serrano D, et al. The acute treatment of episodic and chronic migraine in the US. Cephalalgia 2009;29: 891-7
17. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo controlled study. Headache 2004;44: 669-73 (Pubitemid 38931897)
18. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. nonearly intervention in acute migraine: 'act when mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008;28: 383-91 (Pubitemid 351341454)
19. Silberstein SD, Mannix LX, Goldstein J, et al. Multimechanism (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 2008;71: 114-21
20. Tfelt-Hansen P, Rolan P. b-Adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams &Wilkins, 2006: 519-28
21. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991;31: 333-40
22. Diener HC, Tfelt-Hansen P, Dahlöf C. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. Eur Neurol 2004;251: 943-50 (Pubitemid 39119312)
23. Toda N, Tfelt-Hansen P. Calcium antagonists in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams &Wilkins, 2006: 539-44
24. Celano CM, Freudenreich O, Fernandez-Robles C, et al. Depressogenic effects of medications: a review. Dialogues Clin Neurosci 2011;13: 109-25
25. Silberstein SD, Tfelt-Hansen P. Antiepileptic drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Goadsby PJ, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams &Wilkins, 2006: 545-51
26. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52: 281-6
27. Klapper JA. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17: 103-8
28. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2003;58: 1652-9
29. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman's: the pharmacological basis of therapeutics. 9th ed. New York (NY): McGraw Hill, 1996: 461-80
30. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376: 645-55
31. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med 2008;9: 175-85 (Pubitemid 351285412)
32. Holroyd KA, Cottrell C, O'Donnel FJ, et al. Effect of preventive (b blocker) treatment, behavioural migraine management, or their combination on outcomes of optimized acute treatment in frequent migraine: randomised controlled trial. BMJ 2010;341: c4871
33. Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29: 784-91
34. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42 Suppl. 1: S3-9 (Pubitemid 34136620)
35. International Headache Society Committee on Clinical Trials in Migraine (Tfelt-Hansen P, Chairman). Guidelines for controlled trials of drugs in migraine: first edition. Cephalalgia 1991;11: 1-12
36. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12 Suppl. 1: 1-27
37. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. Epub 2011 Dec 5
38. Lyngberg AC, Rasmussen BK, Jørgensen T, et al. Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study. Eur J Epidemiol 2005;20: 1007-14 (Pubitemid 41752619)
39. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 2010;24: 539-48
40. Ferrari MD, FärkkiläM, Reuter U;European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan: a randomised proof-of-concept trial. Cephalalgia 2010;30: 1170-8
41. Lipton RB, Bigal ME, Diamond M, et al.;AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68: 343-9 (Pubitemid 46184209)
42. Olesen J, Tfelt-Hansen P, Ashina M. Finding new drug targets for the treatment of migraine attacks. Cephalalgia 2009;29: 909-20
43. Wienecke T, Olesen J, Oturai PS, et al. Prostaglandin E2(PGE2) induces headache in healthy subjects. Cephalalgia 2009;29: 509-19
44. Antonova M, Wienicke T, Maubach K, et al. The pharmacological effect of BGC-1531, a novel prostanoid EP (4) receptor antagonist, in the prostaglandin E (2) human model of headache. J Headache Pain 2011;12: 551-9
45. Ploug KB, Baun M, Hay-Schmidt A. Presence and vascular pharmacology of KATP channel subtypes in rat central and peripheral tissues. Eur J Pharmacol 2010;637: 109-17
46. Anttila V, Stefansson H, Kallela M, et al.;International Headache Genetic Consortium. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010;42: 869-73
47. Goadsby PJ, Charbit AR, Andreou AP, et al. Neurobiology of migraine. Neuroscience 2009;161: 327-41